The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium:A collaborative cognitive and neuroimaging genetics project by Blokland, Gabriëlla A M et al.
                          Blokland, G. A. M., Del Re, E. C., Mesholam-Gately, R. I., Jovicich, J.,
Trampush, J. W., Keshavan, M. S., ... Petryshen, T. L. (2017). The Genetics
of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS)
consortium: A collaborative cognitive and neuroimaging genetics project.
Schizophrenia Research. https://doi.org/10.1016/j.schres.2017.09.024
Peer reviewed version
Link to published version (if available):
10.1016/j.schres.2017.09.024
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at http://www.schres-journal.com/article/S0920-9964(17)30586-8/fulltext#s0100 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Schizophrenia Research xxx (2017) xxx–xxx
SCHRES-07538; No of Pages 12
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresThe Genetics of Endophenotypes of Neurofunction to Understand
Schizophrenia (GENUS) consortium: A collaborative cognitive and
neuroimaging genetics projectGabriëlla A.M. Blokland a,b,c,d, Elisabetta C. del Re c,e,f, Raquelle I. Mesholam-Gately c,g, Jorge Jovicich h,
Joey W. Trampush i,j,k,l, Matcheri S. Keshavan c,g,m, Lynn E. DeLisi c,e, James T.R. Walters n, Jessica A. Turner o,p,
Anil K. Malhotra i,j,k, Todd Lencz i,j,k, Martha E. Shenton c,e,f,q, Aristotle N. Voineskos r,s, Dan Rujescu t,u,
Ina Giegling t, René S. Kahn v, Joshua L. Roffman b,c,w, Daphne J. Holt b,c,w, Stefan Ehrlich c,w,x, Zora Kikinis c,f,
Paola Dazzan y,z, Robin M. Murray y,z, Marta Di Forti y,z, Jimmy Lee aa, Kang Sim aa, Max Lam aa,
Rick P.F. Wolthusen c,w,x, Sonja M.C. de Zwarte v, Esther Walton v, Donna Cosgrove ab, Sinead Kelly ac,ad,
Nasim Maleki b,c,w, Lisa Osiecki a, Marco M. Picchioni y,z, Elvira Bramon y,z,ae, Manuela Russo y,z,
Anthony S. David y,z, Valeria Mondelli y,z, Antje A.T.S. Reinders y,z, M. Aurora Falcone y,z, AnnetteM. Hartmann t,
Bettina Konte t, Derek W. Morris af, Michael Gill ac, Aiden P. Corvin ac, Wiepke Cahn v, New Fei Ho aa,
Jian Jun Liu ag, Richard S.E. Keefe ah, Randy L. Gollub b,c,w, Dara S. Manoach b,c,w, Vince D. Calhoun o,ai,
S. Charles Schulz aj, Scott R. Sponheim aj, Donald C. Goff c,ak, Stephen L. Buka al, Sara Cherkerzian am,
Heidi W. Thermenos b,c,g, Marek Kubicki c,f,q,w, Paul G. Nestor c,e,an, Erin W. Dickie r, Evangelos Vassos y,z,
Simone Ciufolini y,z, Tiago Reis Marques y,z, Nicolas A. Crossley y,z, Shaun M. Purcell c,d,ao,ap,
Jordan W. Smoller a,b,c,d, Neeltje E.M. van Haren v, Timothea Toulopoulou y,aq,ar, Gary Donohoe ac,af,
Jill M. Goldstein b,c,am,am, Larry J. Seidman b,c,g,†, Robert W. McCarley c,e,†, Tracey L. Petryshen a,b,c,d,⁎
a Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, United States
b Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
c Department of Psychiatry, Harvard Medical School, Boston, MA, United States
d Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, United States
e Department of Psychiatry, Veterans Affairs Boston Healthcare System, Brockton, MA, United States
f Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States
g Massachusetts Mental Health Center Public Psychiatry Division, Beth Israel Deaconess Medical Center, Boston, MA, United States
h Center for Mind/Brain Sciences (CiMEC), University of Trento, Trento, Italy
i Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Division of Northwell Health, Manhasset, NY, United States
j Division of Psychiatry Research, The Zucker Hillside Hospital, Division of Northwell Health, Glen Oaks, NY, United States
k Hofstra Northwell School of Medicine, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, United States
l BrainWorkup, LLC, Los Angeles, CA, United States
m University of Pittsburgh Medical Center, Pittsburgh, PA, United States
n Department of Psychological Medicine, Cardiff University, Cardiff, United Kingdom
o The Mind Research Network, Albuquerque, NM, United States
p Department of Psychology and Neuroscience Institute, Georgia State University, GA, United States
q Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
r Kimel Family Translational Imaging Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Department of Psychiatry,
Faculty of Medicine, University of Toronto, Toronto, ON, Canada
s Department of Psychiatry and Institute of Medical Science, University of Toronto, Toronto, ON, Canada
t Department of Psychiatry, Psychotherapy and Psychosomatics, University of Halle-Wittenberg, Halle, an der Saale, Germany
u Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
v Brain Centre Rudolf Magnus, Department of Psychiatry, University Medical Centre Utrecht, Utrecht, The Netherlands
w MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States
x Division of Psychological & Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
y Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom
z National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, United Kingdom
aa Institute of Mental Health, Woodbridge Hospital, Singapore⁎ Corresponding author at: Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA
02114, United States.
E-mail address: tpetryshen@mgh.harvard.edu (T.L. Petryshen).
† Deceased
https://doi.org/10.1016/j.schres.2017.09.024
0920-9964/© 2017 Elsevier B.V. All rights reserved.
Please cite this article as: Blokland, G.A.M., et al., The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS)
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017), https://doi.org/10.1016/j.schres.2017.09.024
2 G.A.M. Blokland et al. / Schizophrenia Research xxx (2017) xxx–xxxab The Cognitive Genetics and Cognitive Therapy Group, Department of Psychology, National University of Ireland, Galway, Ireland
ac Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland
ad Laboratory of NeuroImaging, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
ae Mental Health Neuroscience Research Department, UCL Division of Psychiatry, University College London, United Kingdom
af Cognitive Genetics and Cognitive Therapy Group, Neuroimaging and Cognitive Genomics (NICOG) Centre and NCBES Galway Neuroscience Centre, School of Psychology and Discipline of
Biochemistry, National University of Ireland, Galway, Ireland
ag Genome Institute, Singapore
ah Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States
ai Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM, United States
aj Department of Psychiatry, University of Minnesota, Minneapolis, MN, United States
ak Nathan S. Kline Institute for Psychiatric Research, Department of Psychiatry, New York University Langone Medical Center, New York, NY, United States
al Department of Epidemiology, Brown University, Providence, RI, United States
am Department of Medicine, Division of Women's Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
an Laboratory of Applied Neuropsychology, University of Massachusetts, Boston, MA, United States
ao Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States
ap Division of Psychiatric Genomics, Departments of Psychiatry and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
aq Department of Psychology, Bilkent University, Bilkent, Ankara, Turkey
ar Department of Psychology, The University of Hong Kong, Pokfulam, Hong Kong, SAR, ChinaPlease cite this article as: Blokland, G.A.M.,
consortium: A collaborative cognitive and na b s t r a c ta r t i c l e i n f oArticle history:
Received 15 June 2017
Received in revised form 15 September 2017
Accepted 20 September 2017
Available online xxxxBackground: Schizophrenia has a large genetic component, and the pathways from genes to illnessmanifestation
are beginning to be identiﬁed. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia
(GENUS)Consortium aims to clarify the role of genetic variation in brain abnormalities underlying schizophrenia.
This article describes the GENUS Consortium sample collection.
Methods:We identiﬁed existing samples collected for schizophrenia studies consisting of patients, controls, and/
or individuals at familial high-risk (FHR) for schizophrenia. Samples had single nucleotide polymorphism (SNP)
array data or genomic DNA, clinical and demographic data, and neuropsychological and/or brain magnetic reso-
nance imaging (MRI) data. Data were subjected to quality control procedures at a central site.
Results: Sixteen research groups contributed data from 5199 psychosis patients, 4877 controls, and 725 FHR in-
dividuals. All participants have relevant demographic data and all patients have relevant clinical data. The sex
ratio is 56.5% male and 43.5% female. Signiﬁcant differences exist between diagnostic groups for premorbid
and current IQ (both p b 1× 10−10). Data from a diversity of neuropsychological tests are available for 92% of par-
ticipants, and 30% have structuralMRI scans (half also havediffusion-weightedMRI scans). SNP data are available
for 76% of participants. The ancestry composition is 70% European, 20% East Asian, 7% African, and 3% other.
Conclusions: The Consortium is investigating the genetic contribution to brain phenotypes in a schizophrenia
sample collection of N10,000 participants. The breadth of data across clinical, genetic, neuropsychological, and
MRI modalities provides an important opportunity for elucidating the genetic basis of neural processes underly-
ing schizophrenia.







Clinical presentation of schizophrenia varies among individuals, but
in general is characterized by positive (hallucinations, delusions), nega-
tive (social withdrawal), and disorganization symptoms, cognitive im-
pairments, altered brain structure and function, and severe deﬁcits in
global and social functioning. There is a generalized cognitive impair-
ment, aswell as speciﬁc deﬁcits across cognitive domains including pro-
cessing speed, attention, working memory, verbal memory, and
executive functioning, that are present as early as the pre-morbid
state during childhood and persist through chronic stages of illness
(Lewandowski et al., 2011). There is consistent evidence from schizo-
phrenia neuroimaging studies for ventricular enlargement, reduced
gray matter volume of cortical and subcortical brain regions, and re-
ducedwhitematter volume and fractional anisotropy of predominantly
fronto-temporal tracts (Bora et al., 2011; Haijma et al., 2013; Shenton et
al., 2001; van Erp et al., 2016). Unaffected relatives of schizophrenia pa-
tients exhibit milder cognitive deﬁcits and brain structural abnormali-
ties (Boos et al., 2007; Keshavan et al., 2010; Thermenos et al., 2013),
suggesting these abnormalities are risk factors for the disorder rather
than secondary effects. The molecular mechanisms underlying these
brain abnormalities are only beginning to be unraveled, which has hin-
dered the identiﬁcation of rational targets for developing better
treatments.
A practical approach for elucidating the disease biology is identifying
genes that confer risk and characterizing their functionwithin the brain.et al., The Genetics of Endop
eur..., Schizophr. Res. (2017),It is long known that schizophrenia has a large genetic component, with
heritability between 64 and 81% (Lichtenstein et al., 2009; Sullivan et al.,
2003). Genome-wide association studies (GWAS) of schizophrenia
case/control datasets by the Psychiatric Genomics Consortium (PGC)
have identiﬁed over 100 chromosomal loci that have genome-wide sig-
niﬁcant evidence for association (PGC Schizophrenia Working Group,
2014). GWAS results indicate that schizophrenia is a polygenic disorder,
for which thousands of common genetic variants with modest individ-
ual effects act in aggregate to increase disease liability (Psychosis
Endophenotypes International Consortium et al., 2014; Purcell et al.,
2009; Ripke et al., 2013). Rare variants further contribute to schizophre-
nia liability (CNV and Schizophrenia Working Groups of the Psychiatric
Genomics Consortium; Psychosis Endophenotypes International
Consortium, 2017; Malhotra and Sebat, 2012).
A promising approach to translate these genetic ﬁndings into an un-
derstanding of the neural processes involved in schizophrenia is to eval-
uate their relevance to disease endophenotypes (Gottesman and Gould,
2003). In this context, cognitive measures have a moderate to high her-
itability (h2 = 0.2–0.7) (Seidman et al., 2015; Stone and Seidman,
2016), while volumetric and diffusion brainmeasures are highly herita-
ble (h2 = 0.6–0.8) (Blokland et al., 2012, 2017). Common genetic vari-
ation (based on SNPs) explains a substantial proportion of this
heritability, estimated at h2 = 0.3–0.4 for cognitive (Hatzimanolis et
al., 2015; Robinson et al., 2015) and brain volume phenotypes (Ge et
al., 2015).Moderate to high genetic correlations between schizophrenia
and cognitive and brain structural phenotypes (rg = 0.5–0.8) suggest ahenotypes of Neurofunction to Understand Schizophrenia (GENUS)
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2016; Lee et al., 2016). Indeed, polygenic risk for schizophrenia is signif-
icantly associated with prefrontal inefﬁciency during working memory
performance in patients and controls (Walton et al., 2013a; Walton et
al., 2013b), as well as lower cognitive performance among healthy pop-
ulations (Germine et al., 2016; Hubbard et al., 2016; Lencz et al., 2014;
Liebers et al., 2016) and schizophrenia patients (Martin et al., 2015).
Speciﬁc genetic risk variants have also been associatedwith altered cog-
nition and brain structure among patients (Donohoe et al., 2010, 2013;
Lencz et al., 2010; Martin et al., 2015; Wassink et al., 2012; Yeo et al.,
2014) although some studies are negative (van Scheltinga et al.,
2013), possibly due to the use of small samples that are prone to incon-
sistent results. Analyses of large, well-phenotyped samples consisting of
both psychosis patients and control individuals will be important for
clarifying the role of genetic risk variants in brain abnormalities relevant
to illness.
With this in mind, the GENUS Consortium aims to improve knowl-
edge of the contribution of genetic variation to schizophrenia brain ab-
normalities by investigating relevant brain traits in a large,
comprehensively phenotyped sample collection. The GENUS Consor-
tium draws upon the efforts of sixteen research groups that have previ-
ously collected samples consisting of psychosis patients (predominantly
schizophrenia), unaffected controls, and/or unaffected familial high-risk
(FHR) individuals assessed for neuropsychological function and/or
brain structure, all of which have genome-wide SNP data or genomic
DNA. Assembly of these samples into one harmonized collection sub-
stantially increases the statistical power compared to the individual
samples alone. The large, well-phenotyped GENUS sample collection
provides a prime opportunity to investigate the genetic basis of brain
abnormalities in psychosis in order to gain insight into the underlying
neuralmechanisms. The purpose of this article is to describe the design,
composition, and data components of the sample collection, while sub-
sequent articles will focus on data analyses.
2. Methods
2.1. Collection of samples
Research groups that had previously collected samples for the pur-
pose of schizophrenia studies were identiﬁed from the psychiatric ge-
netics community and publications. Criteria for inclusion were:
availability of SNP genotype data or genomic DNA, as well as demo-
graphic, neuropsychological and/or magnetic resonance imaging
(MRI) data, and, for patients, clinical data.
2.2. Informed consent and ethics approval
The lead principal investigator for each sample veriﬁed approval
from their institutional ethics committee for sharing human subject
data. All research participants provided written informed consent (or
legal guardian consent and subject assent). Ethics approval for the
GENUS Consortium study at the central site was obtained from the Part-
ners Healthcare (USA) Institutional Review Board. All data were
anonymized prior to transfer to the central site.
2.3. Clinical and demographic data
For demographic data, all research groups had collected data on age
at recruitment, sex, and education level, and most groups had also col-
lected data on socioeconomic status and handedness. Clinical data
were available for patients and, for some samples, FHR individuals. All
site-speciﬁc clinical variables were renamed according to a common
variable naming convention. Raw data underwent quality control anal-
yses at the central site for expected value ranges and outliers. To enable
comparison across sites, we computed basic descriptives (means and
standard deviations for quantitative variables; frequency tables forPlease cite this article as: Blokland, G.A.M., et al., The Genetics of Endop
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017),categorical variables) and plotted histograms to check for unexpected
differences in data distributions. Antipsychotic medication dosages,
both current and lifetime, where available, were converted to chlor-
promazine equivalents based on published dosage equivalence esti-
mates (Gardner et al., 2010; Woods, 2003).2.4. Neuropsychological data
The speciﬁc neuropsychological tests ranged across samples, al-
though all research groups administered tests within the Measurement
and Treatment Research to Improve Cognition in Schizophrenia
(MATRICS) consensus cognitive battery (Nuechterlein et al., 2008) or
tests with similar design and scoring.We therefore focused onMATRICS
tests and tests thatmeasure similar cognitive constructs as theMATRICS
tests. Additionally, we included visuospatial ability and verbal ability
tests, as most groups administered these tests. All site-speciﬁc test var-
iables were renamed according to a common variable naming conven-
tion. The raw data from each test were checked for errors by
calculating descriptive statistics and visualizing data distributions for
each study sample. Premorbid IQ was estimated from reading tests (or
vocabulary if reading tests were not available), and current IQ from
Wechsler Adult Intelligence Scale (WAIS) subtests (see Supplementary
Materials).2.5. Neuroimaging data
For those research groups that acquired MRI scans, we required 1.5
or 3 Tesla ﬁeld strength, and availability of control scans in order to nor-
malize the imaging data. We imposed no restrictions on the scanner
vendor or model. As an initial assessment of quality, a subset of 12
scans from each sample (3male patients, 3 female patients, 3 male con-
trols, 3 female controls) were visually inspected for consistent artifacts
using 3DSlicer (http://www.slicer.org; Fedorov et al., 2012), including
partial brain coverage, wrap-around and motion artifacts, and gross
signal/contrast inhomogeneity. Further quality control analyses were
carried out upon receipt of the full dataset and will be described
elsewhere.2.6. SNP genotype data
Each research group provided raw SNP array genotype data, when
available, or genomic DNA extracted fromwhole blood, buffy coat or sa-
liva (≥2 ng/μL) that we genotyped on the Illumina Inﬁnium PsychArray.
Although most participants had self-reported ancestry information, we
assigned ancestry bymerging genotype call data from each samplewith
the 1000 Genomes Reference Panel (Sudmant et al., 2015; The 1000
Genomes Project Consortium et al., 2015), and applying multidimen-
sional scaling using Plink software (Purcell et al., 2007) to extract ances-
try principal components. Model-based clustering (R function ‘Mclust’)
was applied to classify participants into ancestral populations as deﬁned
by the 1000 Genomes Reference Panel. Basic quality control analyses of
raw genotype data consisted of removing unplaced SNPs and
conﬁrming consistency between reported sex and X chromosome
genotype.2.7. Statistical analyses
Quantitative demographic data from patient, control, and FHR
groups were compared using ANOVA. Chi-square tests compared the
relative proportions of males/females, ancestral populations, and hand-
edness across groups. For all statistical tests, an uncorrected alpha of
0.05 was applied.henotypes of Neurofunction to Understand Schizophrenia (GENUS)
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3.1. Central data management
Sixteen research groups contributed data from 19 samples
consisting of 5199 patients, 4877 controls, and 725 FHR participants
(unaffected relatives of psychosis patients), totaling 10,801 participants.
Table 1 lists the data from each sample that was provided to the central
site (Massachusetts General Hospital). Details for each data modality
are provided in the sections below. Each research group provided the
central site with detailed sample information (see Supplementary Ma-
terials), including recruitment (source, target diagnosis, illness stage
[e.g. ﬁrst-episode sample]), inclusion/exclusion criteria (ranges of age,
IQ, and years of education; substance andmedication use,MRI contrain-
dications), and data modalities, which the central site reviewed andTable 1
Description of the GENUS Consortium Sample Collection.#
Acronym Sample Site GWAS Array












CIDAR/VA Boston Center for Intervention
Development and Applied
Research/VA Healthcare System
Boston, USA Illumina OmniExpress
COGS-UK Cognition and Genetics in
Schizophrenia & Bipolar Disorder
Cardiff, UK Illumina Inﬁnium
OmniExpressExome-8
GAP Genetics and Psychosis
First-Episode Study
London, UK Illumina HumanCore-2
Exome BeadChip
IMH-SIGNRP Institute of Mental Health –







IMH-STCRP Institute of Mental Health –
Singapore Translational and




KCL-MFS King's College London – Maudsley
Family Study
London, UK Affymetrix 6.0
KCL-MTS King's College London – Maudsley
Twin Study
London, UK Affymetrix 6.0
L&R Language and Risk in
Schizophrenia
Boston, USA Illumina Inﬁnium
PsychArray*





MGH Massachusetts General Hospital Boston, USA Illumina Inﬁnium
PsychArray*
NEFS New England Family Study Boston, USA Illumina Inﬁnium
PsychArray*








TCD/NUIG Trinity College Dublin/National





UMCU-SZ1 University Medical Center Utrecht






UMCU-SZ2 University Medical Center Utrecht











Eur = European-derived ancestry; FHR = familial high-risk.
# Data in this table are based on the total GENUS sample collection; data for the subset with
§ All samples with T1 MRI scans also have diffusion-weighted MRI scans except the PHRS, U
‡ Population ancestry determined from genetic data (where available) or self-report.
⁎ Samples genotyped at the central GENUS site.
Please cite this article as: Blokland, G.A.M., et al., The Genetics of Endop
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017),obtained clariﬁcation as necessary. Some samples have been previously
contributed to other research consortia or the datamade available in re-
positories (see Supplementary Materials).
3.2. Demographic and clinical characteristics of samples
Table 2 shows the demographic and clinical characteristics of the 19
samples. The patient diagnoses consist of 76.4% schizophrenia, 8.9%
schizoaffective disorder (SAD), 1.8% schizophreniform disorder (SPD),
6.5% bipolar disorder with psychosis (BD), and 6.3% other psychoses.
Fourteen samples consist of controls and patients with a range of ill-
ness durations, except for one sample (GAP) consists of only ﬁrst-epi-
sode patients and controls. Four of these 14 samples also contain FHR
individuals. Two samples consist of FHR and controls, two samples con-





















123 144 0 56.2 76.1 89 115 0 55.4 76.5
K
741 0 0 73.6 54.7 – – – – –
76 107 6 68.8 60.0 68 101 6 68.0 59.4
835 0 0 58.8 97.3 – – – – –
4 164 160 0 59.6 46.8 132 94 0 56.2 35.0
ina
etrix
150 63 0 55.9 0 243 81 0 62.4 0
-8
420 1012 0 52.9 0 – – – – –
183 120 278 48.0 95.1 – – – – –
127 297 47 42.9 100 63 75 23 60.3 94.5
0 31 44 34.7 74.7 0 33 51 33.3 71.4
112 95 0 72.0 75.3 118 97 0 71.2 76.7
434 0 0 72.4 68.8 61 123 0 65.2 73.2
83 151 33 44.6 86.2 72 155 20 44.5 85.8
0
210 1341 0 50.0 99.6 – – – – –
0 53 77 45.4 41.0 0 46 67 44.3 55.8
a 904 290 0 60.9 99.9 175 312 0 56.9 99.8
0; 97 143 0 68.3 98.6 159 157 0 69.3 99.1
0;
a
233 144 235 58.8 97.5 184 131 212 59.0 93.6
0 219 0 49.3 100 – – – – –
4892 4370 720 56.5 72.2 1364 1520 379 57.4 65.0
genotype data are provided in Supplementary Table 1.
MCU-SZ1, and UMCU-SZ2 samples.
henotypes of Neurofunction to Understand Schizophrenia (GENUS)
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Table 2
Clinical and demographic characteristics of the GENUS Consortium Sample Collection.#
Patients Controls Familial High Risk Statistic df p
N Mean ± SD (Range) N Mean ± SD
(Range)
N Mean ± SD
(Range)
Age (years) 5197 39.3 ± 12.2 (13–82) 4877 39.2 ± 15.8 (8–86) 725 34.9 ± 16.0
(10–85)




Education Level (years) 4697 12.3 ± 2.6 (1–24) 4031 13.3 ± 2.6 (4–26) 721 13.1 ± 3.2 (3–24) F =
163.4
2, 9446 b1 ×
10−10
Premorbid IQ 3145 97.1 ± 15.5
(44–145)
1393 107.6 ± 10.7
(62–145)




2, 4618 b1 ×
10−10
Current IQ 1889 93.8 ± 18.1
(47–155)
2779 113.4 ± 14.9
(67–161)




2, 5267 b1 ×
10−10
Illness Duration (years) 4165 15.1 ± 11.6 (b1–58) – – – – – – –
Age at Onset (years) 4124 23.8 ± 8.6 (1–71) – – – – – – –
Global Assessment of Functioning 1764 59.8 ± 15.9
(11–100)
– – – – – – –
PANSS Positive symptoms 2916 16.3 ± 7.3 (7–47) – – – – – – –
PANSS Negative Symptoms 2912 16.7 ± 7.1 (7–43) – – – – – – –
PANSS General Symptoms 2919 32.0 ± 11.8 (0–93) – – – – – – –
SAPS Positive Symptoms 1533 7.9 ± 12.3 (0–121) – – – – – – –
SANS Negative Symptoms 983 23.6 ± 20.1 (0–103) – – – – – – –
Antipsychotic dose – current CPZEQ 3315 384.2 ± 406.6
(0–5000)
– – – – – – –
Antipsychotic dose – lifetime average
CPZEQ
1433 338.3 ± 365.1
(0–3125)
– – – – – – –
N % N % N %





Atypical 2100 49.1 – – – – – – –
Typical 411 9.6 – – – – – – –
Both Typical and Atypical 544 12.7 – – – – – – –
Naïve/None 474 11.1 – – – – – – –
Unknown Class 324 7.6 – – – – – – –
No information 422 9.9 – – – – – – –
Diagnosis
Schizophrenia 3973 76.4 – – – – – – –
Schizoaffective Disorder 465 8.9 – – – – – – –
Schizophreniform Disorder 93 1.8 – – – – – – –
Bipolar Psychosis 338 6.5 – – – – – – –
Other Psychosis 204 3.9 – – – – – – –
Psychosis Unknown Type 126 2.4 – – – – – – –




European 3686 71.2 3396 69.7 632 87.2 – – –
East Asian 697 13.5 1117 22.9 3 0.4 – – –
African 510 9.9 152 3.1 57 7.9 – – –
American (Predominantly Latino) 140 2.7 30 0.6 3 0.4 – – –
South Asian 50 1.0 35 0.7 7 1.0 – – –
Mixed 28 0.5 11 0.2 10 1.4 – – –
No information 68 1.3 135 2.8 13 1.8
Handedness (right/other; %
right-handed)
2322/260 89.9 2378/252 90.4 609/59 91.2 χ2 = 1.0 2 0.60
CPZEQ=chlorpromazine 100mg equivalent; df=degrees of freedom; PANSS=Positive andNegative Syndrome Scale; SANS=Scale for theAssessment of Negative Symptoms; SAPS=
Scale for the Assessment of Positive Symptoms; SD = Standard Deviation.
# Data in this table are based on the total GENUS sample collection; data for the subset with genotype data are provided in Supplementary Table 2.
5G.A.M. Blokland et al. / Schizophrenia Research xxx (2017) xxx–xxxrange of illness duration (b1–58 years) and the inclusion of FHR partic-
ipants, the sample collection has a wide age range (8–86 years). The sex
composition is 56.5%male and 43.5% female. There are signiﬁcant differ-
ences between the patient, control, and FHR groups in age (younger
FHR), sex ratio (more male patients), years of education (fewer in pa-
tients), and ancestral population (all p b 1 × 10−10; Table 2), but not
in handedness. These differences must be adjusted in analyses, or
matched subsets selected.
The most common clinical data across the samples are the Positive
and Negative Syndrome Scale (PANSS; 54.7% of patients) (Kay et al.,
1987; Peralta and Cuesta, 1994), Scale for the Assessment of Negative
Symptoms (SANS) (Andreasen, 1983) and Scale for the Assessment of
Positive Symptoms (SAPS) (Andreasen, 1984) (29.5% of patients), and
Global Assessment of Functioning (GAF; 33.9% of patients) (American
Psychiatric Association, 2000).Please cite this article as: Blokland, G.A.M., et al., The Genetics of Endop
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017),Current or lifetime average dose of antipsychotic medication (chlor-
promazine equivalents) (Gardner et al., 2010;Woods, 2003) is available
for 63.8% or 27.6% of patients, respectively, and 21.2% of patients have
both dosage estimates. Dosages are similar to other clinical samples
(Eum et al., 2017; van Erp et al., 2016), suggesting that this patient col-
lection is representative of and generalizable to the clinical population.
3.3. Neuropsychological measures
All 19 samples have neuropsychological data from 4892 patients
(75.6% schizophrenia, 9.4% SAD, 1.7% SPD, 6.8% BD, 6.5% other psycho-
sis), 4370 controls, and 720 FHR individuals (9982 participants or
92.4% of sample; Table 1). The most common tests administered across
the samples are shown in Table 3, with highest overlap across samples
for Digit Symbol Coding, Verbal Fluency, and Word List Learning.henotypes of Neurofunction to Understand Schizophrenia (GENUS)
https://doi.org/10.1016/j.schres.2017.09.024
Table 3
Core neuropsychological tests available for GENUS Consortium samples.#
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x UMD* SDRT HVLT
CIDAR-VA BACS* x MCCB* x ACPT UMD* WMS-III* HVLT-R* WMS-III or CMS
COGS-UK BACS* x MCCB* x UMD* WMS-III* HVLT-R*













































NEFS WAIS-R COWAT ACPT WAIS-R
Digit Span
CVLT or CVLT-II WMS-R or
WMS-III
PAGES WAIS-R-DE x Semantic/Phonemic 3–7 CPT WAIS-R-DE
Digit
Span/Arithmetic




x A-X CPT Cogtest
SWM
Cogtest







UMCU-SZ2 WAIS-III-NL H-Q CPT WAIS-III-NL
Arithmetic
AVLT










































N patients 3488 1549 3956 2337 703 2895 1866 1097 1644 3488 1452 388
N controls 3535 1116 2826 1410 1025 1080 3248 610 904 2519 1017 705
N FHR 396 196 280 119 381 79 347 76 89 384 82 177
N total 7419 2861 7062 3866 2109 4054 5461 1783 2637 6391 2551 1270
Visual Learning & Memory Reasoning/Problem Solving Visuo-spatial Ability Verbal Ability
Sample BVMT-R* Other TMT-B WCST Other Block Design Other Vocabulary Other
CAMH RBANS Figure Recall x Stroop RBANS JOLO/Figure Copy
CATIE 64-C WISC-III Mazes
CIDAR-VA BVMT-R* 64-C NAB Mazes* WASI WASI D-KEFS Proverbs
COGS-UK BVMT-R* NAB Mazes*
GAP WMS-III VisRep x CANTAB SOC WAIS-III WAIS-III MR WAIS-III INF
IMH-SIGNRP BACS TOL
IMH-STCRP 64-P BACS TOL WASI MR/Benton JOLO
KCL-MFS WMS-R VisRep x CANTAB IDED WAIS-R WAIS-R OA/PA/PC WAIS-R WAIS-R COM/INF/SIM
KCL-MTS WMS-R-UK VisRep/VisPA x CANTAB IDED WAIS-III-UK WAIS-III-UK OA/PA/PC WAIS-III-UK WAIS-III-UK COM/INF/SIM
L&R BVMT-R* 64-C NAB Mazes* WASI WASI D-KEFS Proverbs
MCIC BVRT/WMS-III Faces x TOL WAIS-III WAIS-III WAIS-III SIM
MGH 128-C/64-C WAIS-III WAIS-III MR/OA/PA/PC WAIS-III WAIS-III COM/INF/SIM
NEFS WMS-III Faces/Rey CFT Recall 128-P Stroop WAIS-R WAIS-R PA/Rey CFT Copy WAIS-R WAIS-R COM/INF; RAN
PAGES WMS-R-DE FigMem/VisRep/VisPA x 128-C TOL-DE WAIS-R-DE WAIS-R-DE OA/PA/PC WAIS-R-DE WAIS-R-DE COM/INF/SIM
PHRS CNB VOLT 128-P Cogtest Go-No-Go
TCD/NUIG WMS-III Faces/CANTAB PAL x CANTAB IDED/SART WAIS-III-R-UK WAIS-III-R-UK MR WAIS-III-R-UK WAIS-III-R-UK SIM
UMCU-SZ1 Stroop WAIS-III-R-NL WAIS-III-R-NL PA WAIS-III-R-NL WAIS-III-R-NL COM
UMCU-SZ2 NAB Mazes*/RST WAIS-III-NL WAIS-III-NL INF
ZHH BVMT-R* x 128-P NAB Mazes*/Stroop
N patients 897 1604 836 1376 3555 2260 1615 1754 2048
N controls 328 1628 1408 835 2781 2744 3131 2425 2617
N FHR 48 317 145 134 350 522 33 285 567
N total 1273 3549 2389 2345 6686 5526 4779 4464 5232
128-P, 128-C = 128-card paper, computerized version; 64-P, 64-C = 64-card paper, computerized version; ACPT = Auditory CPT; AVLT = Auditory Verbal Learning Test; BACS = Brief Assessment of Cognition in Schizophrenia; BVMT-R = Brief
Visuospatial Memory Test-Revised; BVRT = Benton Visual Retention Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CFT = Complex Figure Test; CMS = Children's Memory Scale; CNB = Computerized Neurocognitive
Battery; COWAT=Controlled OralWord Association Test; CPT(−IP)= Continuous Performance Test (Identical Pairs); CVLT(−SF)= California Verbal Learning Test (Short Form); DE=German version; D-KEFS=Delis–Kaplan Executive Function
System; FigMem= Figural Memory; HVLT = Hopkins Verbal Learning Test; IDED = Intra-Extra Dimensional Set Shifting; JOLO = Judgment of Line Orientation; MAE =Multilingual Aphasia Examination; MCCB =MATRICS Consensus Cognitive
Battery; NAB=Neuropsychological Assessment Battery; NL=Dutch version; PAL= Paired Associates Learning; RAN= Rapid Automatized Naming; RBANS= Repeatable Battery for the Assessment of Neuropsychological Status; RST= Response
Shifting Task; RVIP=Rapid Visual Information Processing; SART=SustainedAttention to Response Task; SDRT=Spatial Delayed Response Task; SOC=Stockings of Cambridge; SWM=SpatialWorkingMemory; TOL=Tower of London; TMT-A, B
= Trail Making Test Part A, B; UK = British version; UMD = University of Maryland; VerbPA = Verbal Paired Associates; VisMemSpan = Visual Memory Span; VisPA = Visual Paired Associates; VisRep = Visual Reproduction; VLMT = Verbal
Learning and Memory Test; VLT = Verbaler Lern Test; VOLT = Visual Object Learning Test; WAIS =Wechsler Adult Intelligence Scale (Subtests: COM= Comprehension; INF = Information; MR =Matrix Reasoning; OA = Object Assembly; PA
= Picture Arrangement; PC= Picture Completion; SIM= Similarities); WASI=Wechsler Abbreviated Scale of Intelligence;WCST=Wisconsin Card Sorting Test;WISC=Wechsler Intelligence Scale for Children;WMS=Wechsler Memory Scale.
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tests and number of participants. There are substantial differences in
the mean premorbid IQ and mean current IQ between diagnostic
groups (both p b 1 × 10−10; Table 2). The mean premorbid and cur-
rent IQ of controls and FHR individuals are higher than the popula-
tion mean of 100, as previously reported by other psychosis studies
(Hill et al., 2013; Seidman et al., 2015). However, the difference of
~10 IQ points between the GENUS patients and controls is consistent
with the literature (Khandaker et al., 2011; Woodberry et al., 2008).
Among the controls, current IQ is notably higher than premorbid IQ.
The high current IQ is predominantly driven by samples that used
few (2–4) WAIS subtests, which may overestimate current IQ com-
pared to samples that used many subtests (i.e., full-scale IQ)
(Axelrod, 2002). The higher current IQ may also be due to a ceiling
effect, where the reading tests used to estimate premorbid IQ have
a lower maximum score (~130) thanWAIS subtests used to estimate
current IQ (maximum 160).3.4. Neuroimaging data
Thirteen samples have T1-weighted structural MRI scans from 1364
patients (74.4% schizophrenia, 7.9% SAD, 3.8% SPD, 5.3% BD, 8.6% other
psychosis), 1520 controls, 379 FHR individuals (3263 participants or
30% of sample; Table 1). Quality evaluation of a subset of scans from
each sample discounted systematic gross errors and indicated that all
datasets are high quality. In addition to the T1-weighted acquisitions, 10
samples have diffusion-weighted MRI scans from 1931 participants, and
9 samples have T2-weighted structural scans from 1821 participants.
Table 4 lists the scanners and primary scan parameters for each sample.
Full scan acquisition parameters are provided in the Supplementary
Materials.Table 4







CAMH 1.5 T GE Echospeed IR-SPGR 0.78 × 0.7
CIDAR-VA 3 T GE Signa HDxt
Echospeed
IR-SPGR 1.0 × 1.0 ×
3 T Siemens Trio Tim MP-RAGE 1.0 × 1.0 ×
GAP 3 T GE Signa HDx MP-RAGE 1.01 × 1.0
IMH-SIGNRP 3 T Philips Intera Achieva TFE 0.9 × 0.9 ×
KCL-MTS 1.5 T GE Signa
Advantage
SPGR 0.78 × 0.7
1.5 T GE Signa
Advantage
SPGR 0.78 × 0.7
L&R 3 T Siemens Trio Tim MP-RAGE 1.0 × 1.0 ×
MCIC 1.5 T Siemens Sonata GRE 0.7 × 0.7 ×
3 T Siemens Trio Tim MP-RAGE 0.625 × 0.
1.5
1.5 T Siemens Sonata GRE 0.625 × 0.
1.5
MGH 3 T Siemens Trio Tim ME-MP-RAGE 1.2 × 1.2 ×
3 T Siemens Trio Tim MP-RAGE 1 × 1 × 1.3
NEFS 1.5 T Siemens Avanto MP-RAGE 1.0 × 1.0 ×
1.5 T Siemens Sonata MP-RAGE 1.0 × 1.0 ×
1.5 T Siemens Sonata MP-RAGE 1.0 × 1.0 ×
3 T Siemens Trio Tim MP-RAGE 1.0 × 1.0 ×
1.5 T GE Genesis Signa EFGRE 0.94 × 0.9
PHRS 1.5 T GE Genesis Signa SPGR 1.25 × 1.2
TCD/NUIG 3 T Philips Intera Achieva TFE 0.9 × 0.9 ×
1.5 T Siemens Magnetom
Symphony
MP-RAGE 0.45 × 0.4
UMCU-SZ1 1.5 T Philips NT Intera FFE 1.0 × 1.0 ×
UMCU-SZ2 1.5 T Philips Achieva FFE 1.0 × 1.0 ×
DW-MRI = Diffusion-Weighted MRI; EFGRE = Enhanced Fast Gradient Echo; FFE = Fast Fie
Recovery) Spoiled Gradient Recalled; (ME-)MP-RAGE = (Multi-Echo) Magnetization Prepared
Please cite this article as: Blokland, G.A.M., et al., The Genetics of Endop
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017),3.5. SNP genotype data
As detailed in the Supplementary Materials, 15 of the 19 samples
had previously acquired raw SNP genotype data from 7478 participants
(69.2%). For 10 samples, only a proportion of participants had been ge-
notyped. Four of the 19 samples had genomic DNA from 978 partici-
pants (9.1%), of which 947 (8.8%) participants had sufﬁcient DNA
quality and quantity for genotyping on the Illumina Inﬁnium
PsychArray at the central site. Table 1 lists the SNP arrays used for
each sample. Supplementary Table 1 lists the number of genotyped par-
ticipants in each sample and Supplementary Table 2 provides the demo-
graphic and clinical characteristics. Of the total 8425 participants with
genotype data, 164 participants were excluded during quality control
analyses due to low (b98%) genotype call rate, resulting in 8261 partic-
ipants with genotype data suitable for imputation (4099 patients, 3851
controls, 306 FHR). Further quality control and imputation procedures
will be described elsewhere. The mean call rate across the cleaned
dataset is 99.8% (range 99.3%–99.9%). The sample collection has 80%
power to detect a genetic variant that explains 0.5% of the variance of
a phenotype at a genome-wide signiﬁcant alpha = 5 × 10−8.
The ancestry breakdown based on genotype data is 70.2% European
(2835 patients, 2703 controls, 264 FHR), 19.5% East Asian (624 patients,
982 controls, 1 FHR), 7.3% African (454 patients, 111 controls, 35 FHR),
2.0% American (predominantly Latino; 138patients, 28 controls, 3 FHR),
and 1.0% other ancestry (53 patients, 27 controls, 3 FHR).
4. Discussion
This article provides a general description of the GENUS Consortium
and its sample collection, which is the largest known dataset of psycho-
sis patients, controls, and FHR individuals with data spanning genetics,








8 × 1.5 23 1000 2.6 × 2.6 × 2.6
1.0 51 900 1.67 × 1.67 × 1.7
1.33 60 700 2.0 × 2.0 × 2.0
1 × 1.2 32 1300 2.4 × 2.4 × 2.4
0.9 15 800 0.9 × 0.9 × 3.0
8 × 1.5 64 1300 2.5 × 2.5 × 2.5
8 × 1.5 64 1300 2.5 × 2.5 × 2.5
1.0 60 700 2.0 × 2.0 × 2.0
1.5 60 700 2.0 × 2.0 × 2.0
625 × 12 1000 2.0 × 2.0 × 2.0
625 × 12 1000 2.0 × 2.0 × 2.0
1.2 6 1000 1.375 × 1.375 × 3.0
– – –
1.33 60 700 2.0 × 2.0 × 2.0
1.33 6 600 2.0 × 2.0 × 2.0
1.5 – – –
1.33 60 700 2.0 × 2.0 × 2.0
4 × 1.5 – – –
5 × 1.5 – – –
0.9 15 800 1.75 × 1.75 × 2.2
5 × 0.9 – – –
1.2 – – –
1.2 – – –
ld Echo; GE = General Electric; GRE = Gradient Recalled Echo; (IR-)SPGR = (Inversion
Rapid Acquisition Gradient Echo; TFE = Turbo Field Echo.
henotypes of Neurofunction to Understand Schizophrenia (GENUS)
https://doi.org/10.1016/j.schres.2017.09.024
9G.A.M. Blokland et al. / Schizophrenia Research xxx (2017) xxx–xxxThis dataset enables large-scale investigations of brain-based pheno-
types. Due to data sharing restrictions of many of the individual sam-
ples, the full dataset is currently only available to external researchers
through collaboration with GENUS Consortium members. The extent
of data and large size of the GENUS dataset, aswell as the breadth of ex-
pertise of the GENUS Consortiummembers, provide a host of opportu-
nities for analyses. For example, examining sex differences in disease-
related phenotypes is an important but often overlooked aspect of psy-
chiatric studies (Goldstein et al., 2013) that can be addressed with this
large, well-phenotyped sample collection.
The GENUS Consortium differs in several aspects from other large-
scale efforts investigating the genetic architecture of cognition and neu-
roanatomy relevant to psychosis (e.g., COGENT, ENIGMA, B-SNIP, Brain
Genomics Superstruct Project, Philadelphia Neurodevelopmental Co-
hort) (Franke et al., 2016; Germine et al., 2016; Holmes et al., 2015;
Lee et al., 2016; Lencz et al., 2014; Tamminga et al., 2013). A key differ-
ence is that many other studies do not have data for both cognition and
brain structuremodalities from the same participants. Bridgingmultiple
brain phenotype modalities, as in the GENUS sample collection, is im-
portant for heterogeneous disorders such as schizophrenia that are de-
ﬁned by diverse symptoms and abnormalities whose relationships are
mostly unknown. Another difference is the GENUS subject-level data
are stored at the central site, allowing for stringent quality control and
site comparability analyses, and the option for mega-analyses across
the entire dataset, whereas someother studies are limited tometa-anal-
ysis of results generated by each site separately.
A major strength of the GENUS sample collection is the existence of
extensive data across patients, controls, and FHR individuals that enable
analyses of genetic effects in multiple diagnostic groups. While informa-
tive genetic ﬁndings are emerging from large healthy cohorts, this is cur-
rently lacking in psychosis cohorts, and it remains unclear whether
genetic factors inﬂuencing brain structure and function in healthy cohorts
have the same effect in psychiatric patients. The GENUS Consortium anal-
yses will initially focus on relating schizophrenia genetic risk variants
identiﬁed by prior GWAS with the cognitive and brain structural pheno-
types available in this sample collection. While the ENIGMA Consortium
did not detect signiﬁcant effects of schizophrenia genetic risk variants
on subcortical volumes in mixed diagnosis and healthy individuals
(Franke et al., 2016), a study of cortical thickness and surface area report-
ed that a substantial proportion (30–45%) of the heritability is explained
by schizophrenia genetic risk variants (Lee et al., 2016). This suggests
that some brain structural measures may be more genetically related to
schizophrenia than others, or that genetic relationships differ in diseased
and healthy brain. In addition, GWAS of cognitive performance and brain
regional volumes have detected novel genetic associations (Adams et al.,
2016; Davies et al., 2015; Hibar et al., 2015; Trampush et al., 2017) that
could be further investigated in the GENUS sample collection.
Regarding genetic analyses, theGENUS sample collection is best suited
for characterizing SNPs, polygenic factors, and pathways identiﬁed by
GWAS, such as the PGC GWAS mega-analyses (PGC Schizophrenia
WorkingGroup, 2014), for effects on brain-based phenotypes, or replicat-
ing ﬁndings from other genetic studies of cognition or brain structure.
Due to the small effect sizes of common genetic variants, our dataset is
notwell powered for GWAS discovery. SNP-based heritability approaches
(e.g., GCTA) require approximately 4000 subjects for 80% power to esti-
mate heritability as low as 20% (Visscher et al., 2014), a reasonable as-
sumption for cognitive and brain volume traits (Franke et al., 2016;
Trampush et al., 2017); therefore, some of our phenotypes (e.g. letter-
number span tests, WAIS Digit Symbol Coding) are suitable for this ap-
proach. Rare variant association studies require enormous samples for ad-
equate statistical power (Auer and Lettre, 2015; Zuk et al., 2014),
therefore our dataset is not sufﬁcient on its own for such analyses. The
availability of multiple phenotypes enables a breadth of analyses, with
the caveat that signiﬁcance thresholdsmust be adjusted formultiple test-
ing, although accounting for correlations between phenotypes and other
data reduction methods could allow for more lenient thresholds. ThePlease cite this article as: Blokland, G.A.M., et al., The Genetics of Endop
consortium: A collaborative cognitive and neur..., Schizophr. Res. (2017),statistical power of our dataset could also bemaximized bymerging phe-
notypes into one phenotype, such as Spearman's ‘g’, in which data from
manyneuropsychological tests are used toderive a singlemeasure of gen-
eral cognitive ability (Spearman, 1904).
There are considerable challenges to combining data acquired by
many research groups. The heterogeneity in the data collected and the
protocols used by each group requires careful harmonization of the
data to maximize comparability between the samples and minimize
confounds. Our harmonization approaches will be described in greater
detail in subsequent data-based articles. Brieﬂy, we are applying
methods that use controls from each sample to standardize the data
(i.e., generate Z scores), as has been reported for neuropsychological
data (Toulopoulou et al., 2010) and structural MRI data (Segall et al.,
2009; Wilke et al., 2014). Further, variability in multi-site imaging
data due to different scanner models and ﬁeld strengths, acquisition
protocols, and image segmentation methods (Han et al., 2006) can be
minimized by processing all scans using a consistent segmentation rou-
tine, which enables detection of subtle effects (Fennema-Notestine et
al., 2007), including gray matter loss in schizophrenia datasets (Segall
et al., 2009). Regarding clinical data, positive and negative symptom
data can be converted between the PANSS and SANS/SAPS, the most
common clinical scales in our dataset, using regression-based equations
(van Erp et al., 2014). As for the limited medication dosage information
of our dataset, this can be addressed partially by conﬁrming ﬁndings
from the full cohort in the subset withmedication data to rule outmed-
ication confounds. We are harmonizing the genotype data from various
SNP arrays by imputing genotypes based on a reference panel to gener-
ate a common set of SNPs across all samples, an accepted approach in
the ﬁeld (PGC Schizophrenia Working Group, 2014). Although hetero-
geneous data collected by multiple sites is not ideal, the large volume
of available legacy data with deep phenotypic and genotype informa-
tion warrants maximizing its use by generating one merged dataset
that has far greater statistical power than the individual samples.
In summary, the GENUS Consortium sample collection is a valuable
resource that builds upon previous efforts by individual research groups
and complements other psychosis datasets. This high-powered sample
collection integrates measures of brain structure, cognition, and genet-
ics for studying the biological basis of psychosis through original analy-
ses and collaborative replication studies. There will be the opportunity
for multiple publications from these data, including articles focusing
on harmonization and genetic analyses of the cognitive data and imag-
ing data, and publications that incorporate multi-modal data. The rich
phenotypic data are expected to provide new insights into neural func-
tions that are disrupted in psychosis.
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